These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 19083253

  • 1. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
    Brunel-Guitton C, Rivard GE, Galipeau J, Alos N, Miron MC, Therrien R, Mitchell G, Lapierre G, Lambert M.
    Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
    [Abstract] [Full Text] [Related]

  • 2. Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience.
    Gumus E, Karhan AN, Hizarcioglu-Gulsen H, Demir H, Ozen H, Saltik Temizel IN, Dokmeci Emre S, Yuce A.
    Eur J Med Genet; 2021 Nov; 64(11):104339. PubMed ID: 34500086
    [Abstract] [Full Text] [Related]

  • 3. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Nov; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 4. [Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years].
    Quijada Fraile P, Martín Hernández E, Teresa García-Silva M.
    Med Clin (Barc); 2011 Sep; 137 Suppl 1():43-5. PubMed ID: 22230125
    [Abstract] [Full Text] [Related]

  • 5. Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.
    Elstein D, Cohn GM, Wang N, Djordjevic M, Brutaru C, Zimran A.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):119-23. PubMed ID: 20727796
    [Abstract] [Full Text] [Related]

  • 6. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 15; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 7. Divergent phenotypes in Gaucher disease implicate the role of modifiers.
    Goker-Alpan O, Hruska KS, Orvisky E, Kishnani PS, Stubblefield BK, Schiffmann R, Sidransky E.
    J Med Genet; 2005 Jun 15; 42(6):e37. PubMed ID: 15937077
    [Abstract] [Full Text] [Related]

  • 8. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 15; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 9. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
    El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK.
    J Inherit Metab Dis; 2006 Feb 15; 29(1):92-8. PubMed ID: 16601874
    [Abstract] [Full Text] [Related]

  • 10. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.
    Choy FY, Zhang W, Shi HP, Zay A, Campbell T, Tang N, Ferreira P.
    Blood Cells Mol Dis; 2007 Feb 15; 38(3):287-93. PubMed ID: 17196853
    [Abstract] [Full Text] [Related]

  • 11. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
    Grigorescu-Sido P, Drugan C, Alkhzouz C, Zimmermann A, Coldea C, Denes C, Grigorescu MD, Cret V, Bucerzan S.
    Eur J Intern Med; 2010 Apr 15; 21(2):104-13. PubMed ID: 20206881
    [Abstract] [Full Text] [Related]

  • 12. Gaucher disease: studies of phenotype, molecular diagnosis and treatment.
    Rice EO, Mifflin TE, Sakallah S, Lee RE, Sansieri CA, Barranger JA.
    Clin Genet; 1996 Mar 15; 49(3):111-8. PubMed ID: 8737974
    [Abstract] [Full Text] [Related]

  • 13. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight.
    Ucar SK, Coker M, Argin M, Akman S, Kara S, Simsek DG, Darcan S.
    Mol Genet Metab; 2009 Jan 15; 96(1):50-1. PubMed ID: 19006678
    [Abstract] [Full Text] [Related]

  • 14. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B.
    Mol Genet Metab; 2014 Nov 15; 113(3):213-8. PubMed ID: 25127542
    [Abstract] [Full Text] [Related]

  • 15. Cessation of enzyme replacement therapy in Gaucher disease.
    Grinzaid KA, Geller E, Hanna SL, Elsas LJ.
    Genet Med; 2002 Nov 15; 4(6):427-33. PubMed ID: 12509713
    [Abstract] [Full Text] [Related]

  • 16. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
    Chan LL, Lin HP.
    Med J Malaysia; 2002 Sep 15; 57(3):348-52. PubMed ID: 12440275
    [Abstract] [Full Text] [Related]

  • 17. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease.
    Arıkan-Ayyıldız Z, Yuce A, Uslu-Kızılkan N, Demir H, Gurakan F.
    Pediatr Blood Cancer; 2011 Apr 15; 56(4):664-6. PubMed ID: 21298757
    [Abstract] [Full Text] [Related]

  • 18. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease.
    Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, Barton NW.
    Blood Cells Mol Dis; 2000 Aug 15; 26(4):285-90. PubMed ID: 11042029
    [Abstract] [Full Text] [Related]

  • 19. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
    Charrow J, Dulisse B, Grabowski GA, Weinreb NJ.
    Clin Genet; 2007 Mar 15; 71(3):205-11. PubMed ID: 17309642
    [Abstract] [Full Text] [Related]

  • 20. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.
    Davies EH, Erikson A, Collin-Histed T, Mengel E, Tylki-Szymanska A, Vellodi A.
    J Inherit Metab Dis; 2007 Nov 15; 30(6):935-42. PubMed ID: 17994286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.